Telix Pharmaceuticals (NASDAQ:TLX) Receives “Outperform” Rating from Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a report issued on Wednesday, Benzinga reports. They currently have a $22.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 84.10% from the company’s current price.

Several other brokerages have also weighed in on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday, September 15th. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday. Finally, Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $20.50.

Telix Pharmaceuticals Stock Performance

Shares of TLX stock opened at $11.95 on Wednesday. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $13.11. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. The company’s fifty day simple moving average is $11.32 and its 200-day simple moving average is $10.41.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth about $1,731,000. Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. XY Capital Ltd grew its stake in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after buying an additional 58,739 shares during the last quarter. Lazard Asset Management LLC increased its holdings in shares of Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after buying an additional 39,400 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares during the last quarter.

Key Stories Impacting Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Strategic radiopharmaceutical expansion: Telix agreed to acquire ITM in a deal valued at up to $2.35 billion, including $1.65 billion in upfront consideration and up to $700 million in additional payments tied to regulatory and sales milestones. The combination is intended to create a larger radiopharmaceutical platform and strengthen Telix’s access to medical radioisotopes. Telix Pharmaceuticals Lands $2.35 Billion Deal
• Positive Sentiment: Improved analyst sentiment: Royal Bank of Canada upgraded Telix from “Hold” to “Moderate Buy,” potentially supporting the stock by signaling greater confidence in the company’s outlook following the ITM announcement. RBC Upgrades Telix Pharmaceuticals
• Positive Sentiment: Pipeline and supply rationale: Management’s research and development presentation emphasized Telix’s oncology pipeline and the strategic importance of securing isotope supply, which could improve manufacturing reliability and support future product launches. Telix Research and Development Day Transcript
• Neutral Sentiment: Share-issuance flexibility: Telix received ASX waivers concerning the timing of shares issued as acquisition consideration, facilitating the transaction but highlighting that equity issuance will be an important part of funding the deal. Telix Receives ASX Waivers
• Negative Sentiment: Deal-related selling pressure: Telix’s stock fell sharply after the announcement as investors focused on the transaction’s size, potential dilution from issuing Telix shares, integration risk and the need for ITM’s lead drug to achieve approval and sales targets. Telix Stock Drops Following ITM Merger Deal

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.